Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells

IUBMB Life

Volumn 48, Issue 4, 1999, Pages 425-428

  Hong, Ro Kim ^a   Chang, Hoon Lee ^a   Yung, Hyun Choi ^b   Ho, Sung Kang ^a   Han, Do Kim ^a  

^a Pusan National University   (South Korea)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cyclin B1; G2 M arrest; Geldanamycin; P27(KIP1)

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; GELDANAMYCIN; HERBIMYCIN A; PROTEIN KINASE; REGULATOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVITY; ERYTHROLEUKEMIA CELL; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0032705608     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/152165499306810     Document Type: Article

References (22)

1. Hartwell, L. H., and Kastan, M. B. (1994) Cell cycle control and cancer. Science 266, 1821-1828.
2. Morgan, D. O. (1995) Principles of CDK regulation. Nature 374, 131-134.
3. Arellano, M., and Moreno, S. (1997) Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29, 559-573.
4. DeBoer, C., Meulman, P. A., Wnuk, R. J., and Peterson, D. H. (1970) Geldanamycin, a new antibiotic. J. Antibiot. 23, 442-447.
5. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89, 239-250.
6. Whitesell, L., Mimnaugh, E. G., DeCosta, B., Myers, C. E., and Neckers, L. M. (1994) Inhibition of heat shock protein HSP90-pp60v-src hetero-protein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91, 8324-8328.
7. Sullivan, W., Stensgard, B., Caucutt, G., Bartha, B., McMahon, N., Alnemri, E. S., Litwack, G., and Toft, D. (1997) Nucleotides and two functional states of hsp90. J. Biol. Chem. 272, 8007-8012.
8. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol. 6, 2198-2206.
9. Whitesell, L., Shifrin, S. D., Schwab, G., and Neckers, L. M. (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 52, 1721-1728.
10. Yamaki, H., Iguchi-Ariga, S. M., and Ariga, H. (1989) Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group. J. Antibiot. 42, 604-610.
11. Yamaki, H., Nakajima, M., Seimiya, H., Saya, H., Sugita, M., and Tsuruo, T. (1995) Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. J. Antibiot. 48, 1021-1026.
12. Stepanova, L., Leng, X., Parker, S. B., and Harper, J. W. (1996) Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10, 1491-1502.
13. Blagosklonny, M. V., Toretsky, J., Bohen, S., and Neckers, L. (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA 93, 8379-8383.
14. An, W. G., Schnur, R. C., Neckers, L., and Blagosklonny, M. V. (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol. 40, 60-64.
15. Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., and Neckers, L. M. (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell. Biol. 16, 5839-5845.
16. Krek, W., and Nigg, E. A. (1991) Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J. 10, 3331-3341.
17. Groshong, S. D., Owen, G. I., Grimison, B., Schauer, I. E., Todd, M. C., Langan, T. A., Sclafani, R. A., Lange, C. A., and Horwitz, K.B. (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol. Endocrinol. 11, 1593-1607.
18. Sherr, C. J., and Roberts, J. M. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
19. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
20. Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187-5190.
21. Zeng, Y. X., and el-Deiry, W. S. (1995) Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12, 1557-1564.
22. Alpan, R. S., and Pardee, A. B. (1996) p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 7, 893-901.